Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
23.07.2013 14:00:00

Quarterly and Full-Year Guidance Reaffirmed, Management Changes, Semi-Annual Dividends, and Conference Call Schedules - Research Report on Thoratec, Hill-Rom, Teleflex, Cooper, and ICU Medical

NEW YORK, July 23, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Thoratec Corporation (NASDAQ: THOR), Hill-Rom Holdings, Inc. (NYSE: HRC), Teleflex Incorporated (NYSE: TFX), The Cooper Companies, Inc. (NYSE: COO), and ICU Medical, Inc. (NASDAQ: ICUI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Thoratec Corporation Research Report

On July 18, 2013, Thoratec Corporation (Thoratec) announced that it will report its Q2 2013 operating results on July 31, 2013. On the same day, the Company will hold a conference call at 1:30 p.m. PDT / 4:30 p.m. EDT to discuss Thoratec's financial results and operating activities. The call is open to all interested parties and will be hosted by Gary F. Burbach, President and CEO, and Taylor C. Harris, Vice President and CFO. In its Q1 2013 results release, the Company had reaffirmed its full-year 2013 revenue guidance to be in the range of $490 million to $510 million. GAAP net income was expected to be $1.32 to $1.42 per diluted share, whereas non-GAAP net income was expected to be $1.76 to $1.86 per diluted share. The Full Research Report on Thoratec Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-18/THOR]

--

Hill-Rom Holdings, Inc. Research Report

On July 17, 2013, Hill-Rom Holdings, Inc. (Hill-Rom) announced that the Company has begun an external search for a new CFO to replace Mark Guinan, who has resigned to accept a position with another company. The Company also reported that Michael Macek, Hill-Rom's Vice President and Treasurer, will act as interim CFO until the search is complete. Additionally, the Company will announce its preliminary unaudited financial results for Q3 FY 2013 (period ended June 30, 2013) on Wednesday, July 24, 2013 after the close of the NYSE. The Company expects to report adjusted EPS of approximately $0.49, which is within the range of its previous guidance. Hill-Rom expects revenue to be approximately $424 million, an increase of 4% YoY. The Company will also host a conference call and live webcast on July 25, 2013, starting 8:00 a.m. - 9:00 a.m. ET to discuss the results. The Full Research Report on Hill-Rom Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-18/HRC]

--

Teleflex Incorporated Research Report

On July 17, 2013, Teleflex Incorporated (Teleflex) announced that it will release its Q2 2013 financial results on July 31, 2013, before market opens. On the same day, the Company will host an investor conference call at 8:00 a.m. ET. An audio replay of the call will be available on the Company website from July 31, 2013, 10:00 a.m. ET to August 7, 2013, 11:59 p.m. ET. In its Q1 2013 results release, Teleflex provided financial estimates for full-year 2013. Constant currency revenue was expected to grow from 11% to 13%, while adjusted diluted EPS was expected to be in the range of $4.70 to $4.90. The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-18/TFX]

--

The Cooper Companies, Inc. Research Report

On July 11, 2013, The Cooper Companies, Inc. (Cooper) declared a semi-annual dividend of $0.03 per share, consistent with the plan approved by Cooper's Board of Directors to pay annual dividends. The semi-annual dividend is payable on August 6, 2013 to stockholders of record as of July 24, 2013. The Full Research Report on The Cooper Companies, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-18/COO]

--

ICU Medical, Inc. Research Report

On July 18, 2013, ICU Medical, Inc. (ICU Medical) announced its Q2 2013 financial results. The Company reported Q2 2013 revenue of $78.7 million, an increase of 1.8% YoY. Net income for Q2 2013 was $7.4 million, or $0.48 per diluted share, as compared to $9.1 million, or $0.63 per diluted share, in Q2 2012. "Our top-line performance during the quarter was highlighted by continued growth in oncology which was offset by a decrease in critical care. International sales were up 4.4%, while domestic sales increased 0.8% year over year," said Scott Lamb, CFO of ICU Medical. For full-year 2013, the Company lowered its previously announced revenue and earnings guidance due to current business trends in certain market segments. Full-year 2013 revenue is now expected to be in the range of $320 million to $325 million, while diluted EPS is now expected to be in the range of $2.50 to $2.60. The Full Research Report on ICU Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-18/ICUI]

----

EDITOR NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  • For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

  • COMPLIANCE PROCEDURE

    Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

    NOT FINANCIAL ADVICE

    Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

    NO WARRANTY OR LIABILITY ASSUMED

    Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


    SOURCE Investors' Reports

    Nachrichten zu Thoratec Corp.mehr Nachrichten

    Keine Nachrichten verfügbar.

    Analysen zu Thoratec Corp.mehr Analysen

    Eintrag hinzufügen
    Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
    Es ist ein Fehler aufgetreten!

    Aktien in diesem Artikel

    ICU Medical 161,00 0,00% ICU Medical
    Teleflex Inc.Shs 182,00 4,60% Teleflex Inc.Shs